Cover Image
市場調查報告書

慢性腎臟病造成的貧血:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析

Anemia in chronic kidney disease: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365170
出版日期 內容資訊 英文 222 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性腎臟病造成的貧血:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析 Anemia in chronic kidney disease: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 222 Pages
簡介

由於新的HIF抑制劑Roxadustat的投入抵消生技仿製藥的Epogen的侵蝕,推動市場成長。

本報告提供慢性腎臟病的貧血治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,未滿足需求,主要的已上市產品簡介,開發平台趨勢等彙整資料。

預測:慢性腎臟病造成的貧血

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Aranesp (darbepoetin alfa)
  • Auryxia (ferric citrate)
  • DexFerrum (iron dextran)
  • Epogen (epoetin alfa)
  • Feraccru (ferric trimaltol)
  • Feraheme (ferumoxytol)
  • Injectafer (ferric carboxymaltose)
  • Mircera (methoxy polyethylene glycol-epoetin beta)
  • NeoRecormon (epoetin beta)
  • Roxadustat
  • Venofer (iron sucrose)
  • 主要調查技術

由於治療:慢性腎臟病的貧血

  • 摘要整理
  • 主要調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求
  • 未來的治療方法

流行病學:慢性腎臟病造成的貧血

  • 摘要整理
  • 資訊來源、調查手法
  • 預測
  • 流行病學者分析
  • 優勢、規定

已上市藥物:慢性腎臟病造成的貧血

  • 摘要整理
  • 產品概要
  • 產品簡介:Aranesp
  • 產品簡介:Epogen
  • 產品簡介:Mircera
  • 產品簡介:Triferic
  • 產品簡介:Venofer

開發平台:慢性腎臟病造成的貧血

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (開發後期):Auryxia
  • 產品簡介 (開發後期):Feraccru
  • 產品簡介 (開發後期):roxadustat

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13144

The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.

This report addresses the following questions:

  • What does the future look like for the erythropoiesis-stimulating agent (ESA)market, considering recent safety data and treatment guidelines?
  • What are the major concerns and unmet needs in the anemia in CKD market?
  • How will novel pipeline therapies impact the treatment of anemia in CKD?
  • What are the most popular treatment options for anemia in CKD in the US, Japan, and five major EU markets?
  • What are the major factors physicians take into consideration when prescribing treatment?

TABLE OF CONTENTS

FORECAST: ANEMIA IN CHRONIC KIDNEY DISEASE

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Aranesp (darbepoetin alfa)
  • 5. Auryxia (ferric citrate)
  • 6. DexFerrum (iron dextran)
  • 7. Epogen (epoetin alfa)
  • 8. Feraccru (ferric trimaltol)
  • 9. Feraheme (ferumoxytol)
  • 10. Injectafer (ferric carboxymaltose)
  • 11. Mircera (methoxy polyethylene glycol-epoetin beta)
  • 12. NeoRecormon (epoetin beta)
  • 13. Roxadustat
  • 14. Venofer (iron sucrose)
  • 15. Primary Research Methodology

TREATMENT: ANEMIA IN CHRONIC KIDNEY DISEASE

  • 16. Executive Summary
  • 17. Primary Research Methodology
  • 18. Disease Definition and Diagnosis
  • 19. Patient Segmentation
  • 20. Country Treatment Trees
  • 21. Current Treatment Options
  • 22. Prescribing Trends
  • 23. Unmet Needs in Anemia in Chronic Kidney Disease
  • 24. Future Treatment

EPIDEMIOLOGY: ANEMIA IN CHRONIC KIDNEY DISEASE

  • 25. Executive Summary
  • 26. Sources and Methodology
  • 27. Forecast
  • 28. Epidemiologist Insight
  • 29. Strengths and Limitations

MARKETED DRUGS: ANEMIA IN CHRONIC KIDNEY DISEASE

  • 30. Executive Summary
  • 31. Product Overview
  • 32. Product profile: Aranesp
  • 33. Product profile: Epogen
  • 34. Product profile: Mircera
  • 35. Product profile: Triferic
  • 36. Product profile: Venofer

PIPELINE: ANEMIA IN CHRONIC KIDNEY DISEASE

  • 37. Executive Summary
  • 38. Clinical Pipeline Overview
  • 39. Product profile (late stage): Auryxia
  • 40. Product profile (late stage): Feraccru
  • 41. Product profile (late stage): roxadustat
Back to Top